Immunopotentiation and tumor inhibition with levamisole.
Immunopotentiation and tumor inhibition with levamisole.
复制标题
左旋咪唑的免疫增强和肿瘤抑制作用。
DOI：
--
复制
发表时间：
1978
期刊：
影响因子：
--
通讯作者：
D. Sampson
中科院分区：
文献类型：
--
作者：
D. Sampson
免疫增强药物左旋咪唑在体外被发现能增强人淋巴细胞对植物有丝分裂原的反应。然而，该效应具有剂量依赖性，在高浓度下，观察到免疫应答的抑制而非增强。鉴于该药物在治疗人类癌症中的潜在广泛应用，在患有乳腺癌的大鼠中进行了一项研究，以确定是否在肿瘤生长方面观察到类似的剂量反应效应。发现肿瘤抑制具有剂量依赖性，在高剂量下未发生肿瘤抑制，而在低剂量下则抑制了癌症的生长。肿瘤生长速度与脾淋巴细胞对植物有丝分裂原的反应密切相关。在后来的一项研究中，不可能证明左旋咪唑在增强接受手术的患者的免疫反应方面有任何效果。结论：左旋咪唑在体外能够增强人体免疫反应，并且该药物能够抑制大鼠乳腺癌的生长。然而，这些作用是剂量依赖性的，在癌症患者中使用左旋咪唑的临床试验应包括仔细的免疫监测，以确保增强而不是抑制免疫反应。
The immunopotentiating drug, levamisole, was found to augment human lymphocyte responses to vegetable mitogens in vitro. However, the effect was dose-dependent and at high concentrations suppression rather than augmentation of the immune response was observed. In view of the potential widespread use of the drug in the treatment of human cancer, a study was undertaken in rats bearing breast cancer to determine whether a similar dose-response effect would be observed in terms of tumor growth. Tumor inhibition was found to be dose-dependent, and at high doses tumor inhibition did not occur while at lower doses the growth of the cancer was inhibited. The rate of tumor growth correlated well with the responses of splenic lymphocytes to vegetable mitogens. In a later study, it was not possible to show that levamisole had any effect in boosting immune responses of patients undergoing surgery. It is concluded that levamisole is capable of increasing immune responses in man in vitro, and that the drug is able to inhibit the growth of breast cancer in the rat. However, these effects are dose-dependent, and clinical trials of the use of levamisole in patients with cancer should include careful immune monitoring to be sure that augmentation rather than suppression of the immune response is being achieved.